Related Experiment Video
Updated: Dec 30, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective
Antonio Mangieri1, Francesco Gallo2, Alessandro Sticchi2
1GVM Care and Research, Maria Cecilia Hospital, Cotignola, Ravenna, Italy. antonio.mangieri@gmail.com.
Insights
Dual antiplatelet therapy is crucial for preventing adverse events after coronary stenting. Newer agents allow personalized antithrombotic strategies based on patient risk profiles.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Antiplatelet therapy is essential for patients undergoing coronary stenting.
- It significantly reduces adverse clinical events in acute coronary syndrome and stable coronary artery disease.
Purpose of the Study:
- To review the history and evolution of dual antiplatelet therapy.
- To discuss current evidence and future directions in antithrombotic management for coronary artery disease.
Main Methods:
- Literature review of antiplatelet and anticoagulant therapies.
- Analysis of clinical trial data and guidelines.
Main Results:
- Dual antiplatelet therapy is a cornerstone in post-stent treatment.
- Emerging antiplatelet and anticoagulant agents offer tailored treatment options.
Conclusions:
- Personalized antithrombotic strategies are key for managing bleeding and ischemic risks.
- Continued research is vital for optimizing patient outcomes in coronary artery disease.
Abstract:
Antiplatelet therapy, the cornerstone of post coronary stenting antithrombotic therapy, reduces the rate of hard clinical endpoints in patients treated both conservatively and invasively following an acute coronary syndrome, as well as in those patients with chronic stable coronary disease who receive a coronary stent. The development of newer antiplatelet and direct anticoagulant agents provides new options in the antithrombotic management of patients with coronary artery disease, enabling different therapeutic combinations to be tailored to an individual patient's bleeding and ischemic risk profile. In this review, we will summarize the history of dual antiplatelet therapy, discuss the latest evidence and future perspectives in treating patients with coronary artery disease.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures

